Document:

exv10w2

 

Exhibit 10.2

PURCHASE AGREEMENT

     THIS PURCHASE AGREEMENT (the “Agreement”) is entered into as of the 24th day of March, 2005,
by and among Sutura, Inc., a Delaware corporation (the “Company”), and Pandora Select Partners,
L.P., a British Virgin Islands limited partnership (“Pandora”), Whitebox Hedged High Yield
Partners, L.P., a British Virgin Islands limited partnership (“WHHY”) and Whitebox Intermarket
Partners, L.P., a British Virgin Islands limited partnership (“WIP”). Pandora, WHHY and WIP are
individually referred to herein as a
“Purchaser” and together as the “Purchasers.”

R E C I T A L S :

     WHEREAS, in consideration of $780,000, $1,590,000 and $630,000 each (representing $3,000,000
in the aggregate), the Company proposes to issue to Pandora, WHHY and WIP, respectively, and each
such Purchaser desires to severally (and not jointly) purchase, a corresponding secured convertible
promissory notes in the form attached as Exhibit A (each, a “Note” and together, the “Notes”) and
warrants in the form attached as Exhibit B (each, a “Warrant” and together, the “Warrants”) to
purchase (subject to certain adjustments) shares of the Company’s common stock, $0.001 par value
(the “Common Stock”); and

     WHEREAS, the Purchasers and the Company desire to have a portion of the $3,000,000 aggregate
purchase price held in escrow;

     WHEREAS, contingent on the sale and purchase of the above $3,000,000 of Notes and Warrants
(the “First Tranche”), the Company has offered the Purchasers the collective opportunity to
purchase up to an additional $2,000,000 of Notes and Warrants on the same terms as the Notes and
Warrants sold in the First Tranche (the “Option Tranche”);

     NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter
set forth, the parties hereto agree as follows:

SECTION 1. AGREEMENT TO SELL AND PURCHASE

     1.1. Authorization of Transactions. On or prior to the first closing of the transactions
contemplated in this Agreement (the “First Closing”), the Company shall have authorized (as to each
of the First Tranche and the Option Tranche) the sale and issuance to the Purchasers of the Notes,
Warrants and the shares of Common Stock issuable upon conversion of the Notes and upon exercise of
the Warrants (collectively, the “Shares”).

     1.2. Sale and Purchase at First Closing. Subject to the terms and conditions hereof, at the
First Closing, the Company hereby agrees to issue and sell to each Purchaser, and each Purchaser
severally (and not jointly) agrees to purchase from the Company, such Purchaser’s respective Notes
and the Warrants for an aggregate purchase price from all Purchasers of

 

 

$3,000,000. A portion of the aggregate purchase price (the “Escrow Amount”) equal to $2,000,000
will be deposited by the Purchasers with Messerli & Kramer P.A., as escrow agent (the “Escrow
Agent”), to be held in escrow pursuant to the terms of the Escrow Agreement, in the form attached
as Exhibit F (the “Escrow Agreement”) among the Purchasers, the Company and the Escrow Agent.

     1.3. Option Tranche. Contingent on the First Closing, the Company hereby grants the
Purchasers, collectively, the right and option to purchase the Option Tranche at a second closing
(the “Option Tranche Closing”). Unless otherwise agreed in writing among the Purchasers (who may
assign all or a portion of the Option Tranche rights only amongst themselves), each Purchaser may
exercise the Option Tranche to purchase up to an additional $666,667 of Notes and Warrants. Each
Option Tranche Purchaser must give the Company written notice of its intention to exercise all or
part of its share of the Option Tranche (specifying in the notice the amount of the Option Tranche
being exercised) not later than 5:00 p.m., Pacific Time, on the date (the “Option Termination
Date”) that is the later of (i) 180 days following the First Closing or (ii) 120 days following the
effective date of the proposed merger (the “TVG Merger”) of the Company into Technology Visions
Group, Inc., a Delaware corporation (“TVG”). Subject to the terms and conditions hereof, at the
Option Tranche Closing, the Company hereby agrees to issue and sell to each Purchaser, and each
Purchaser severally (and not jointly) agrees to purchase from the Company, such Purchaser’s
respective Option Tranche Note and the Warrant.

SECTION 2. CLOSINGS, DELIVERIES AND PAYMENTS

     2.1. First Closing.

     (a) The First Closing shall take place at 10:00 a.m. on the date hereof at the offices of the
Purchasers’ legal counsel, Messerli & Kramer P.A., in Minneapolis, Minnesota, or at such other time
or place as the Company and the Purchasers may mutually agree (the “First Closing Date”). At the
First Closing, subject to the terms and conditions hereof, the Company will issue, sell and deliver
to each Purchaser its respective Note and Warrant, against payment by each Purchaser of its
allocable portion of the $1,000,000 purchase price by certified check or wire transfer of
immediately available funds. At the First Closing, the Company shall also execute and deliver to
the Purchasers the Amended Registration Rights Agreement in the form attached as Exhibit C (the
“Registration Rights Agreement”), the Amended Security Agreement in the form attached as Exhibit D
(the “Security Agreement”) and the Amended Patent and Trademark Security Agreement in the form
attached as Exhibit E (the “Patent and Trademark Security Agreement”).

     (b) At the First Closing, the Purchasers shall deposit with the Escrow Agent the Escrow
Amount, by certified check or wire transfer of immediately available funds, and the Company shall
deposit with the Escrow Agent each Purchaser’s respective Note (in the principal amount of $520,000
for Pandora, $1,060,000 for WHHY and $420,000 for WIP) and Warrant

- 2 -

 

(the “Escrow Securities”), in each case to be held by the Escrow Agent in accordance with the terms
of the Escrow Agreement.

     2.2. Option Tranche Closing. If one or more of the Purchasers timely exercises all or a
portion of the Option Tranche, the Option Tranche Closing shall take place at 10:00 a.m. on the
date (the “Option Tranche Closing Date”) that is five business days following the earlier of (i)
the full exercise of the Option Tranche by the Purchasers, (ii) the partial exercise of the Option
Tranche by one or more Purchasers and the Company’s receipt of a written waiver from the Purchasers
of their rights to exercise the balance of the Option Tranche or (iii) the Option Termination Date.
At the Option Tranche Closing, subject to the terms and conditions hereof, the Company will issue,
sell and deliver to each exercising Purchaser its respective Note and Warrant, against payment by
each Purchaser of its allocable portion of the Option Tranche purchase price by certified check or
wire transfer of immediately available funds. The Option Tranche Closing Date and the First Closing
Date are collectively referred to herein as the “Closing Dates”.

     2.3. Escrow Amount Closing.

     (a) If, within sixty (60) days after the First Closing Date, the Company gives written notice
to Whitebox Advisors, LLC (“Whitebox Advisors”), as agent for the Purchasers, and the Escrow Agent
certifying that the “as simple as 1-2-3” SuperStich product is experiencing success rates
equivalent to or better than success rates experienced by comparable closure devices in the
industry and containing the written statement of an independent third-party (which party shall be
reasonably acceptable to both the Company and Whitebox Advisors) confirming that such success rates
are equivalent to or better than success rates experienced by comparable closure devices in the
industry, the Escrow Amount will be paid by the Escrow Agent to the Company, and the Escrow
Securities will be delivered by the Escrow Agent to the Purchasers.

     (b) Notwithstanding Section 2.3(a) above, each Purchaser may, at its option, direct the Escrow
Agent to pay such Purchaser’s allocable portion of the Escrow Amount to the Company and deliver the
corresponding Escrow Securities to such Purchaser by giving written notice of its intention to the
Escrow Agent and the Company within sixty (60) days after the First Closing Date.

     (c) Payment of the Escrow Amount and the delivery of the Escrow Securities will take place at
10:00 am on the date (the “Escrow Closing Date”) that is five (5) business days following the
receipt by Whitebox Advisors and the Escrow Agent of the Company’s written notice pursuant to
Section 2.3(a) or the receipt by the Company and the Escrow Agent of the Purchaser’s written notice
pursuant to Section 2.3(b) as applicable. At or prior to the Escrow Closing Date, the Company will
have reconfirmed its representations, warranties and agreements contained herein, the Company will
have obtained all third-party consents required in connection herewith, the Company will have
procured, at its expense, UCC-type insurance in form and amount satisfactory to the
Purchasers as to the perfection and priority of their security interest in the Collateral, the
Company shall have paid to Whitebox Advisors a $50,000 cash origination fee

- 3 -

 

related to the transactions and the Company’s counsel will have provided a legal opinion covering
the matters specified in Section 5.1(f).

     (d) If the Company and the Purchasers fail to provide the written notice referred to in
Section 2.3(a) or 2.3(b), as applicable, within sixty (60) days after the First Closing Date, then
the Escrow Agent shall release the Escrow Amount to the Purchasers and the Escrow Securities to the
Company.

SECTION 3. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY

     The Company hereby makes the following representations and warranties to each of the
Purchasers as of the First Closing Date and, as to the 510(k) clearance and CE mark described in
Section 3.16, covenants to so comply with the requirements thereof from and after the First Closing
Date so long as any portion of any of the Notes remain outstanding.

     3.1. Organization, Good Standing and Qualification. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware. The
Company’s only subsidiary is Sutura B.V., which is wholly-owned by the Company and which, in turn,
owns all of the outstanding capital stock of Sutura B.V. France SARL and Sutura GmbH. The Company
has all requisite corporate power and authority to own and operate its properties and assets, to
execute and deliver this Agreement, the Notes, the Warrants, the Registration Rights Agreement, the
Security Agreement and the Patent and Trademark Security Agreement (together, the “Transaction
Documents”), to pledge (subject to receipt of the consent referred to in Section 5.1(a)) certain of
the Company’s assets as described in the Security Agreement and the Patent and Trademark Security
Agreement as security for the Notes (the “Collateral”), to issue and sell the Shares upon
conversion of the Notes and upon exercise of the Warrants, to carry out the provisions of the
Transaction Documents, and to carry on its business as presently conducted and as presently
proposed to be conducted. The Company is duly qualified to do business and is in good standing in
each jurisdiction in which the nature of its activities and of its properties (both owned and
leased) makes such qualification necessary, except for those jurisdictions in which failure to be
so qualified would not have a material adverse effect on the Company, or its business or
properties, taken as a whole.

     3.2. Capitalization. The authorized capital stock of the Company consists of 5,000,000 shares
of Preferred Stock, par value $0.00025 per share, of which, as of the First Closing Date, 352,160
shares are issued and outstanding, and 10,000,000 shares of Common Stock, par value $0.00025 per
share, of which 7,008,628 shares are issued and outstanding. As of the First Closing Date (to be
updated for the Option Tranche Closing Date), and except as disclosed on Schedule 3.2, the Company
has no outstanding options,
warrants or other rights to acquire any capital stock, or securities convertible or exchangeable
for capital stock or for securities themselves convertible or exchangeable for capital stock
(together, “Convertible Securities”). As of the First Closing Date (to be updated for the Option
Tranche Closing Date), and except as disclosed on Schedule 3.2, the Company has no agreement or
commitment to sell or issue any shares of capital stock or Convertible Securities. All issued and
outstanding shares

- 4 -

 

of the Company’s capital stock (i) have been duly authorized and validly issued, (ii) are fully
paid and nonassessable, (iii) are free from any preemptive and cumulative voting rights and (iv)
were issued pursuant to valid exemptions under federal and state securities laws. As of the First
Closing Date (to be updated for the Option Tranche Closing Date), and except as disclosed on
Schedule 3.2, there are no outstanding rights of first refusal or proxy or shareholder agreements
of any kind relating to any of the Company’s securities to which the Company or any of its
executive officers and directors is a party or as to which the Company otherwise has knowledge of.
When issued in compliance with the provisions of the Notes and the Warrants (and upon payment as
provided by the Warrants), the Shares will be validly issued, fully paid and nonassessable, and
will be free of any liens or encumbrances; provided, however, that the Shares may be subject to
restrictions on transfer under applicable state and/or federal securities laws.

     3.3. Authorization; Binding Obligations. All corporate action on the part of the Company,
its officers, directors and shareholders necessary for the authorization of the Transaction
Documents, the performance of all obligations of the Company hereunder and thereunder at each of
the First Closing and the Option Tranche Closing (together, the “Closings”), including the pledge
of the Collateral as security for the Notes, and the authorization, sale, issuance and delivery of
the Shares upon conversion of the Notes and upon exercise of the Warrants has been taken or will be
taken prior to each of the Closings. The Transaction Documents, when executed and delivered, will
be valid and binding obligations of the Company enforceable in accordance with their terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of
general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii) to the extent that the enforceability of the indemnification provisions of the
Registration Rights Agreement may be limited by applicable laws. Except as to the Purchasers’
Option Tranche rights hereunder, the sale of the Shares upon exercise of the Warrants or upon
conversion of the Notes is not and will not be subject to any preemptive rights or rights of first
refusal.

     3.4. Financial Statements. The Company’s audited consolidated balance sheet at December 31,
2003, and the audited consolidated statements of operations, cash flows and stockholders’ deficit
of the Company for the years ended, December 31, 2003 and 2002, and the Company’s unaudited
consolidated balance sheet at September 30, 2004, and the unaudited consolidated statements of
operations and cash flows of the Company for the nine months ended September 30, 2004 and 2003 (all
of the foregoing together, the “Financial Statements,” with September 30, 2004 being the “Latest
Statement Date” and the consolidated financial statements at and for the nine months ended September 30, 2004
being the “Latest Financial Statements”) fairly present in all material respects, and in accordance
with generally accepted accounting principles consistently applied, the consolidated financial
condition and operating results of the Company as of the respective dates and for the respective
periods covered thereby. The Financial Statements are in the form as publicly filed with the SEC
as Attachment 3 to Amendment No. 3 to the Schedule 14C Information Statement of TVG relating to the
proposed TVG Merger (the “Information Statement”).

- 5 -

 

     3.5. Liabilities. The Company (i) has no material liabilities and (ii) to the best of its
knowledge, has no material contingent liabilities, in each case not otherwise disclosed in the
Latest Financial Statements or on Schedule 3.6, except (A) current liabilities incurred in the
ordinary course of business subsequent to the Latest Statement Date and (B) obligations under
contracts and commitments incurred in the ordinary course of business and not required under
generally accepted accounting principles to be reflected in the Latest Financial Statements, which,
in both cases have not had, either in any individual case or in the aggregate, a material adverse
effect on the Company, or its business or properties, taken as a whole.

     3.6. Certain Agreements and Actions. Except as disclosed in the Financial Statements or on
Schedule 3.6, the Company has not (i) declared or paid any dividends, or authorized or made any
distribution upon or with respect to any class or series of its capital stock during the periods
covered by the Financial Statements or since the Latest Statement Date, (ii) since the Latest
Statement Date, incurred any indebtedness for money borrowed or any other material liabilities out
of the ordinary course of business, (iii) except as set forth in Schedule 3.6, made any loans or
advances to any person, other than ordinary advances for travel or entertainment expenses or (iv)
sold, exchanged or otherwise disposed of any of its assets or rights, other than in the ordinary
course of business.

     3.7. Obligations of or to Related Parties. Except as disclosed on Schedule 3.7, there are no
obligations of the Company to officers, directors or key employees of the Company or, to the
Company’s knowledge, to any members of their immediate families or other affiliates, other than (i)
for accrued salaries, (ii) reimbursement for expenses reasonably incurred on behalf of the Company
and (iii) for other employee benefits made generally available to all employees (including stock
option agreements outstanding under any stock option plan approved by the Board of Directors of the
Company). Except as disclosed on Schedule 3.7, to the Company’s knowledge, none of the officers,
directors or key employees of the Company or, to the Company’s knowledge, any members of their
immediate families or other affiliates, are indebted to the Company or have any direct or indirect
ownership interest in any firm, corporation or other entity with which the Company is affiliated or
with which the Company has a business relationship, or any firm, corporation or other entity that
competes with the Company, except that such officers, directors, employees and members of their
immediate families may own securities (with beneficial ownership not exceeding 2%) in
publicly-traded companies that compete with the Company. Except as disclosed on Schedule 3.7, no officer, director or key
employee of the Company, or, to the Company’s knowledge, any member of their immediate families or
other affiliates, is, directly or indirectly, interested in or a party to any material contract
with the Company. Except as disclosed on Schedule 3.7 or in the Financial Statements, the Company
is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation.

     3.8. Changes. Since the Latest Statement Date, and except as disclosed on Schedule 3.8, there
has not been, to the Company’s knowledge, any event or condition of any character that, either
individually or cumulatively, has materially and adversely affected the business, assets,
liabilities, financial condition, operations or prospects of the Company.

- 6 -

 

     3.9. Title to Properties and Assets; Liens. Except as set forth on Schedule 3.9, the Company
has good and marketable title to its properties and assets, including the properties and assets
reflected in the Latest Financial Statements, in each case subject to no mortgage, pledge, lien,
lease, encumbrance or charge, other than (i) those resulting from taxes that have not yet become
delinquent, (ii) liens and encumbrances that do not materially detract from the value of the
property subject thereto or materially impair the operations of the Company and (iii) those that
have otherwise arisen in the ordinary course of business. With respect to the property and assets
it leases, the Company is in compliance with such leases in all material respects and, to the
Company’s knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances.
All facilities, machinery, equipment, fixtures and other properties owned, leased or used by the
Company which are reasonably necessary to the Company’s conduct of its business are in good
operating condition and repair and are reasonably fit and usable for the purposes for which they
are being used, reasonable wear and tear excepted.

     3.10. Patents and Trademarks. Schedule 3.10 contains a listing of all U.S. and foreign
patents and patent applications, and U.S. and foreign trademarks and service marks and applications
therefor, owned by, assigned to or licensed to the Company. Except as set forth on Schedule 3.10,
the Company owns or has a valid right to use all patents, trademarks, service marks, trade names,
copyrights, trade secrets, information and other proprietary rights and processes necessary for its
business as now conducted and as proposed to be conducted, without any known infringement of the
rights of others. The Company is not aware that any of its employees is obligated under any
contract (including licenses, covenants or commitments of any nature) or other agreement, or
subject to any judgment, decree or order of any court or administrative agency, that would
interfere with their duties to the Company or that would conflict with the Company’s business as
now conducted or proposed to be conducted. None of the execution or delivery of, or the performance
of the transactions contemplated by, the Transaction Documents, the pledge of the Collateral by the
Company to secure the Notes, the carrying on of the Company’s business by the employees of the
Company nor the conduct of the Company’s business as currently conducted or proposed to be
conducted will conflict with or result in a breach of the terms, conditions or provisions of, or
constitute a default under, any contract, covenant or instrument under which any employee is now
obligated. The Company does not believe it is or will be necessary to utilize any inventions,
trade secrets or proprietary information of any of its employees made prior to their employment by
the Company, except for inventions, trade secrets or proprietary information that have been
exclusively assigned to the Company.

     Without limiting the generality of the above, neither of Cardio Medical Solutions, Inc. nor
Nobles LAI Engineering Inc., nor any other entity owned or controlled by officers, directors or key
employees of the Company, own or control any inventions, trade secrets or proprietary information
necessary for or desirable to the Company in connection with and directly related to its business
as now conducted or proposed to be conducted.

- 7 -

 

     Except as set forth in Schedule 3.10, (i) each of the Company’s employees have executed
agreements of confidentiality and non-disclosure as to the Company’s confidential information,
including its intellectual property and trade secrets, and (ii) each of the Company’s employees has
agreed to assign to the Company any and all significant conceptions and ideas for inventions,
improvements and valuable discoveries, whether patentable or not, which are conceived or made by
such employees, solely or jointly with another, during the period of employment, and which are
directly related to the business or activities of the Company and which the employee conceives as a
result of the employee’s employment by the Company (other than inventions for which no equipment,
supplies, facility or trade secret information of the Company was used and which was developed
entirely on the employee’s own time and (1) which does not relate (a) directly to the business of
the Company or (b) to the Company’s actual or demonstrably anticipated research or development or
(2) which does not result from any work performed by the employee for the Company).

     3.11. Compliance with Other Instruments. Except as disclosed on Schedule 3.11, the Company is
not in violation or default of any term of its Certificate of Incorporation or Bylaws, or in any
material respect of any mortgage, indenture, contract, agreement, instrument or contract to which
it is party or by which it is bound or of any judgment, decree, order, writ or, to its knowledge,
any statute, rule or regulation applicable to the Company that would materially and adversely
affect the business, assets, liabilities, financial condition, operations or prospects of the
Company. The execution and delivery of, and the performance of and compliance with the
transactions contemplated by, the Transaction Documents, and the issuance and sale of the Shares
upon conversion of the Notes or upon exercise of the Warrants, will not, with or without the
passage of time or giving of notice, result in any such material violation, or be in conflict with
or constitute a default under any such term, or result in the creation of any mortgage, pledge,
lien, encumbrance or charge upon any of the properties or assets of the Company or the suspension,
revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval
applicable to the Company, its business or operations or any of its assets or properties, except
for such results that would not materially and adversely affect the business, assets, liabilities,
financial condition, operations or prospects of the Company.

     3.12. Litigation. There is no action, suit, proceeding or investigation pending or, to the
Company’s knowledge, currently threatened against the Company that questions the validity of this
Agreement or the other Transaction Documents or the right of the Company to enter into any of such
agreements, or to consummate the transactions contemplated hereby or thereby. Except as disclosed
in the Information Statement or on Schedule 3.12, there is no action, suit, proceeding or
investigation or, to the Company’s knowledge, currently threatened against the Company that might
result, either individually or in the aggregate, in any material adverse change in the assets,
condition, affairs or prospects of the Company, financial or otherwise, or any change in the
current equity ownership of the Company. The foregoing includes, without limitation, actions
pending or threatened involving the prior employment of any of the employees of the Company, their
use in connection with the Company’s business of any information or techniques allegedly
proprietary to any of their former employers or their obligations under any agreements with prior
employers. The Company is not a party or subject

- 8 -

 

to the provisions of any order, writ, injunction, judgment or decree of any court or government
agency or instrumentality.

     3.13. Tax Returns and Payments. The Company has filed all tax returns (federal, state and
local) required to be filed by it. All taxes shown to be due and payable on such returns, any
assessments imposed, and, to the Company’s knowledge, all other taxes due and payable by the
Company on or before the Closing have been paid or will be paid prior to the time they become
delinquent. The Company has not been advised (i) that any of its returns, federal, state or other,
have been or are being audited as of the date hereof or (ii) of any deficiency in assessment or
proposed judgment to its federal, state or other taxes. The Company has no knowledge of any
liability of any tax to be imposed upon the properties or assets of the Company as of the date of
this Agreement that is not adequately provided for.

     3.14. Employees. The Company has no collective bargaining agreements with any of its
employees. The Company is not aware of any labor union organizing activity relating to its
employees. Except as set forth on Schedule 3.14, no employee has any agreement or contract, written
or verbal, regarding his employment. Except as disclosed on Schedule 3.14, the Company is not a
party to or bound by any currently effective employment contract, deferred compensation
arrangement, bonus plan, incentive plan, profit sharing or defined benefit plan, retirement
agreement or other employee compensation plan or agreement. To the Company’s actual knowledge, no
employee of the Company, nor any consultant with whom the Company has contracted, is in violation
of any material term of any employment contract, proprietary information agreement or any other
agreement relating to the right of any such individual to be employed by, or to contract with, the
Company because of the nature of the business to be conducted by the Company; and, to the Company’s
knowledge, the continued employment by the Company of its present employees, and the performance of
the Company’s contracts with
its independent contractors, will not result in any such violation. The Company has not received
any written or oral notice alleging that any such violation has occurred. Except as disclosed on
Schedule 3.14, no employee of the Company has been granted the right to continued employment by the
Company or to any material compensation following termination of employment with the Company. The
Company is not aware that any officer or key employee, or that any group of key employees, intends
to terminate their employment with the Company, nor does the Company have a present intention to
terminate the employment of any officer, key employee or group of key employees.

     3.15. Registration Rights. Except (i) for registration rights granted by the Company pursuant
to a Registration Rights Agreement dated September 17, 2004 (the “Original Registration Rights
Agreement”), (ii) as disclosed on Schedule 3.15 or (iii) required pursuant to the Registration
Rights Agreement, the Company is presently not under any obligation, and has not granted any
rights, to register (as defined in the Registration Rights Agreement) any of the Company’s
presently outstanding securities or any of its securities that may hereafter be issued.

     3.16. Compliance with Laws; Permits; Company Medical Devices. Except as disclosed on
Schedule 3.16, the Company is not in violation of any applicable statute, rule,

- 9 -

 

regulation, order or restriction of any domestic or foreign government or any instrumentality or
agency thereof in respect of the conduct of its business or the ownership of its properties that
would materially and adversely affect the business, assets, liabilities, financial condition,
operations or prospects of the Company. No governmental orders, permissions, consents, approvals
or authorizations are required to be obtained and no registrations or declarations are required to
be filed in connection with the execution and delivery of, and the performance of the transactions
contemplated by, the Transaction Documents, the pledge of the Collateral to secure the Notes or the
issuance of the Shares upon conversion of the Notes or upon exercise of the Warrants, except such
as has been duly and validly obtained or filed, or with respect to any filings that must be made
after the Closing, as will be filed in a timely manner. The Company has all franchises, permits,
licenses and any similar authority necessary for the conduct of its business as now being conducted
by it, the lack of which could materially and adversely affect the business, properties, prospects
or financial condition of the Company and the Company believes it can obtain any similar authority
for the conduct of its business as now conducted or planned to be conducted.

     With respect to the Company’s marketing and sale of minimally invasive vessel closure devices
for surgical applications (which the Company represents are the only products that the Company
manufactures, markets or sells):

	 	(i)	 	The Company has received 510(k) clearance from the U.S. Food & Drug Administration (the “FDA”)
to sell its F8 & F6 SuperStitch® devices, including its Next Generation versions (together, the
“Company Medical Devices”) in the United States;
	 
	 	(ii)	 	The Company has obtained permission from its notified body to place the CE mark on the Company
Medical Devices so as to permit their sale in European Union countries;
	 
	 	(iii)	 	The Company’s 510(k) clearance and CE mark for the Company Medical Devices are in full force
and effect and the Company has not received and anticipates no warning letter or other notice of,
and is unaware of any basis for, revocation, limitation or modification of such 510(k) clearance or
CE marking; and
	 
	 	(iv)	 	The Company manufactures the Company Medical Devices in compliance with FDA quality system
regulations and the EU Medical Device Directive and is otherwise in compliance with all applicable
FDA rules and regulations and EU directives (including the Medical Device Directive) relating to
the manufacture, marketing and sale of the Company Medical Devices, including with respect to
reporting of any device failures or adverse reactions, except where such failure to comply would
not materially and adversely affect the ability of the Company to sell the Company’s Medical
Devices in each EU country.

- 10 -

 

     With respect to any human clinical investigation of new or proposed medical devices by the
Company, or modifications to the Company Medical Devices, the Company is conducting each such
investigation in material compliance with applicable rules and regulations, including by obtaining
any required Investigational Device Exemption or Institutional Review Board approvals.

     3.17. Environmental and Safety Laws. The Company is not in violation of any applicable
statute, law or regulation relating to the environment or occupational health and safety, where
such violation would have a material adverse effect on the Company, and to the Company’s knowledge,
no material expenditures are or will be required in order to comply with any such existing statute,
law or regulation. Without limiting the foregoing:

	 	(i)	 	with respect to any real property owned, leased or otherwise utilized by the Company
(“Real Property”), the Company is not or has not in the past been in violation of any
Hazardous Substance Law which violation could reasonably be expected to result in a
material liability to the Company or its properties and assets;
	 
	 	(ii)	 	neither the Company nor, to the knowledge of the Company, any third party has used,
released, generated, manufactured, produced or stored, in, on, under, or about any Real
Property, or transported thereto or therefrom, any Hazardous Substances that could
reasonably be expected to result in a material liability to the Company under any
Hazardous Substance Law;
	 
	 	(iii)	 	to the knowledge of the Company, there are no underground tanks, whether operative
or temporarily or permanently closed, located on any Real Property that could reasonably
be expected to result in a material liability to the Company
under any Hazardous Substance Law;
	 
	 	(iv)	 	there are no Hazardous Substances used, stored or present at, or on, or to the
knowledge of the Company that could reasonably be expected to migrate onto any Real
Property, except in compliance with Hazardous Substance Laws; and
	 
	 	(v)	 	to the knowledge of the Company, there neither is nor has been any condition,
circumstance, action, activity or event that could reasonably be expected to be a material
violation by the Company of any Hazardous Substance Law, or to result in liability to the
Company under any Hazardous Substance Law.

     For purposes hereof, “Hazardous Substances” means (statutory acronyms and abbreviations having
the meaning given them in the definition below of “Hazardous Substances Laws”) substances defined
as “hazardous substances,” “pollutants” or “contaminants” in Section 101 of the CERCLA; those
substances defined as “hazardous waste,” “hazardous materials” or “regulated substances” by the
RCRA; those substances designated as a “hazardous substance” pursuant to Section 311 of the CWA;
those substances defined as “hazardous materials” in Section 103 of the HMTA; those substances
regulated as a hazardous chemical

- 11 -

 

substance or mixture or as an imminently hazardous chemical substance or mixture pursuant to
Sections 6 or 7 of the TSCA; those substances defined as “contaminants” by Section 1401 of the
SDWA, if present in excess of permissible levels; those substances regulated by the Oil Pollution
Act; those substances defined as a pesticide pursuant to Section 2(u) of the FIFRA; those
substances defined as a source, special nuclear or by-product material by Section 11 of the AEA;
those substances defined as “residual radioactive material” by Section 101 of the UMTRCA; those
substances defined as “toxic materials” or “harmful physical agents” pursuant to Section 6 of the
OSHA; those substances defined as hazardous wastes in 40 C.F.R. Part 261.3; those substances
defined as hazardous waste constituents in 40 C.F.R. Part 260.10, specifically including Appendix
VII and VIII of Subpart D of 40 C.F.R. Part 261; those substances designated as hazardous
substances in 40 C.F.R. Parts 116.4 and 302.4; those substances defined as hazardous substances or
hazardous materials in 49 C.F.R. Part 171.8; those substances regulated as hazardous materials,
hazardous substances, or toxic substances in 40 C.F.R. Part 1910; any chemical, material, toxin,
pollutant, or waste regulated by or in any other Hazardous Substances Laws; and in the regulations
adopted and publications promulgated pursuant to said laws, whether or not such regulations or
publications are specifically referenced herein.

     “Hazardous Substances Law” means any of:

	 	(i)	 	the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended
(42 U.S.C. Section 9601 et seq.) (“CERCLA”);
	 
	 	(ii)	 	the Federal Water Pollution Control Act (33 U.S.C. Section 1251 et seq.) (“Clean Water Act” or
“CWA”);
	 
	 	(iii)	 	the Resource Conservation and Recovery Act (42 U.S.C. Section 6901 et seq.)
(“RCRA”);
	 
	 	(iv)	 	the Atomic Energy Act of 1954 (42 U.S.C. Section 2011 et seq.) (“AEA”);
	 
	 	(v)	 	the Clean Air Act (42 U.S.C. Section 7401 et seq.) (“CAA”);
	 
	 	(vi)	 	the Emergency Planning and Community Right to Know Act (42 U.S.C. Section 11001 et
seq.) (“EPCRA”);
	 
	 	(vii)	 	the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. Section 136 et seq.)
(“FIFRA”);
	 
	 	(viii)	 	the Oil Pollution Act of 1990 (33 U.S.C.A. Section 2701 et seq.);
	 
	 	(ix)	 	the Safe Drinking Water Act (42 U.S.C. Sections 300f et seq.) (“SDWA”);
	 
	 	(x)	 	the Surface Mining Control and Reclamation Act of 1974 (30 U.S.C.

- 12 -

 

	 	 	 	Sections 1201 et seq.) (“SMCRA”);

	 
	 	(xi) 	 	the Toxic Substances Control Act (15 U.S.C. Section 2601 et seq.) (“TSCA”);

	 
	 	(xii)	 	the Hazardous Materials Transportation Act (49 U.S.C. Section 5101 et seq.)
(“HMTA”);
	 
	 	(xiii)	 	the Uranium Mill Tailings Radiation Control Act of 1978 (42 U.S.C.
Section 7901 et seq.) ( “UMTRCA”);
	 
	 	(xiv)	 	the Occupational Safety and Health Act (29 U.S.C. Section 651 et seq.)
(“OSHA”); and
	 
	 	(xv)	 	all other federal, state and local governmental rules which govern Hazardous
Substances, and the regulations adopted and publications promulgated pursuant to all such
foregoing laws.

     3.18. Offering Valid. Assuming the accuracy of the representations and warranties of the
Purchasers contained in Section 4, the offer, sale and issuance of the Notes and the Warrants (and
the Shares issuable upon conversion of the Notes or upon exercise of the Warrants) will be exempt
from the registration requirements of the Securities Act of 1933, as amended (the “Securities
Act”), and will have been registered or qualified (or are exempt from registration and
qualification) under the registration, permit or qualification requirements of the State of
Minnesota.

     3.19. Full Disclosure. None of this Agreement, the Notes, the Warrants, the Registration
Rights Agreement or the Security Agreement contains any untrue statement of a material fact nor, to
the Company’s knowledge and belief, omits to state a material
fact necessary in order to make the statements contained herein or therein not misleading.

     3.20. Insurance. The Company has fire and casualty insurance policies with coverage customary
for companies similarly situated to the Company. The Company’s coverage for product liability is
described on Schedule 3.20.

     3.21. Investment Company Act. The Company is not, and will not use the proceeds from the Notes
in a manner so as to become, an “investment company,” or a company “controlled” by an “investment
company,” within the meaning of the Investment Company Act of 1940, as amended.

     3.22. Security Interest in Collateral. The Company owns the Collateral free and clear of all
claims, liens or encumbrances of any kind except for the security interests granted in such
Collateral pursuant to a Security Agreement and a Patent and Trademark Security Agreement, each
dated September 17, 2004 (the “Original Security Agreements”). Upon consummation of

- 13 -

 

the transactions as contemplated hereby, and subject to the Company’s receipt of consents from the
secured parties under the Original Security Agreements (the “Original Secured Parties”), the
Purchasers will, together with the Original Secured Parties, have a first priority security
interest in the Collateral.

     3.23. Foreign Corrupt Practices; Sarbanes-Oxley.

     (a) Neither the Company, nor to the knowledge of the Company, any agent or other person acting
on behalf of the Company, has (i) directly or indirectly, used any corrupt funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic
political activity, (ii) made any unlawful payment to foreign or domestic government officials or
employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)
failed to disclose fully any contribution made by the Company (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv) violated in any
material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

     (b) The Company is in compliance in all material respects with all provisions of the
Sarbanes-Oxley Act of 2002 that are applicable to it as of each of the Closing Dates.

     3.24. Brokers or Finders. Except as set forth in Schedule 3.24, the Company has not incurred
nor will incur, directly or indirectly, any liability for any brokerage or finders’ fees or agent’s
commissions or any similar charges (whether payable in cash, in equity securities or by a
combination thereof) in connection with this Agreement or any transaction contemplated hereby.

     3.25. Proposed Merger with TVG. The Company has entered into an Agreement and Plan of Merger
dated November 22, 2004 (the “Merger Agreement”) with TVG,
pursuant to which the Company is to consummate the Merger. The Merger Agreement, in the form filed
by TVG as Attachment 2 to the Information Statement, is a true and correct copy of the agreement
between the Company and TVG and is in full force and effect. From and after the date hereof, the
Company will not amend, modify, replace, terminate or abandon the Merger Agreement and the proposed
Merger without first obtaining the written consent of Whitebox Advisors, as agent for the
Purchasers. However, the Company may abandon or terminate the proposed Merger without the consent
of Whitebox Advisors if a majority of the members of the Board of Directors of the Company
determines that such abandonment or termination is in the best interests of the Company and its
stockholders.

     Upon any abandonment or termination of the proposed Merger, the Company will not consummate a
merger with an alternate public company without first obtaining the prior written consent of
Whitebox Advisors as agent of the Purchasers, which it shall not withhold unreasonably. If the
Company identifies a candidate company acceptable to it, the Company will give Whitebox Advisors
written notice describing the proposed alternate transaction. The Purchasers will be deemed to
consent to this proposed alternate merger if the Purchasers (through Whitebox Advisors) do not give
the Company written notice withholding the

- 14 -

 

Purchasers’ consent within 15 business days after Whitebox Advisors receives the Company’s written
notice. In particular, the Company agrees it would be reasonable for the Purchasers (through
Whitebox Advisors) to withhold consent to an alternate merger candidate if:

	 	•	 	Fusion Capital Fund II, LLC, an Illinois limited liability company and current
funding source for TVG (“Fusion Capital”), does not agree to a new Common Stock Purchase
Agreement on substantially the same terms and conditions as its agreement with TVG;
	 
	 	•	 	The Company or the new merger candidate do not reasonably cooperate with the
Purchasers in their due diligence review of the alternate merger candidate and the terms
and conditions of the Company’s proposed merger with it;
	 
	 	•	 	The Purchasers are not reasonably satisfied, in their discretion, with the results of
their above referenced due diligence review; or
	 
	 	•	 	The Purchasers reasonably determine, in their discretion, that a merger with the
alternate merger candidate will not yield substantially equivalent financial returns for
the Purchasers as the contemplated Merger with TVG.

     Assuming that the Purchasers consent to the Company’s alternate merger transaction, or fail to
timely withhold their consent to it, and assuming that the Company consummates any such alternate
merger, all references to TVG in the Transaction Documents will thereafter automatically refer to
the Company’s alternate merger party.

     3.26. Use of Proceeds. The Company will use the proceeds from the purchase of the Notes and
Warrants for general corporate purposes.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

     Each Purchaser hereby severally, but not jointly, represents and warrants to the Company as of
each of the Closing Dates, and agrees, as follows:

     4.1. Authorization. Such Purchaser has full power and authority to enter into this Agreement
and each of the Transaction Documents, and each such agreement, when executed and delivered by such
Purchaser, will be valid and binding obligations of the Purchaser enforceable in accordance with
their terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium
or other laws of general application affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies and (iii) to the extent that the enforceability of the indemnification
provisions of the Registration Rights Agreement may be limited by applicable laws.

     4.2. Investment Representations. The Purchaser understands that neither the offer nor the sale
of the Purchaser’s Note, the Warrant or the Shares has been registered under the

- 15 -

 

Securities Act. The Purchaser also understands that the Purchaser’s Note and Warrant are being
offered and sold pursuant to an exemption from registration contained in the Securities Act based
in part upon the Purchaser’s representations contained in the Agreement. The Purchaser hereby
represents and warrants as follows:

     (a) Purchaser Bears Economic Risk. The Purchaser has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company so
that it is capable of evaluating the merits and risks of its investment in the Company and has the
capacity to protect its own interests. The Purchaser must bear the economic risk of this
investment indefinitely unless the Purchaser’s respective Note or Warrant (or the Shares) are
registered pursuant to the Securities Act, or an exemption from registration is available. Except
as contemplated by the Registration Rights Agreement, the Purchaser has no present intention of
selling or otherwise transferring its respective Note, the Warrant or the Shares, or any interest
therein. The Purchaser also understands that there is no assurance that any exemption from
registration under the Securities Act will be available and that, even if available, such exemption
may not allow the Purchaser to transfer all or any portion of the Purchaser’s respective Note, the
Warrant or the Shares under the circumstances, in the amounts or at the times the Purchaser might
propose.

     (b) Acquisition for Own Account. Except as contemplated by the Registration Rights Agreement,
the Purchaser is acquiring its respective Note, the Warrant and the Shares for the Purchaser’s own
account for investment only, and not with a view towards their public distribution.

     (c) Purchaser Can Protect Its Interest. The Purchaser represents that by reason of its, or of
its management’s, business or financial experience, the Purchaser has
the capacity to protect its own interests in connection with the transactions contemplated in this
Agreement, the Note, the Warrant and the Registration Rights Agreement. Further, the Purchaser is
aware of no publication of any advertisement in connection with the transactions contemplated in
the Agreement.

     (d) Accredited Investor. The Purchaser represents that it is an accredited investor within the
meaning of Rule 501 of Regulation D of the Securities Act

     (e) Residence. The Purchaser represents that it is organized under the laws of the British
Virgin Islands and that its principal office is located in the State of Minnesota.

     (f) Rule 144. The Purchaser acknowledges and agrees that its respective Note and Warrant, and,
if issued, its Shares, must be held indefinitely unless they are subsequently registered under the
Securities Act or an exemption from such registration is available. The Purchaser has been advised
or is aware of the provisions of Rule 144 promulgated under the Securities Act, which permits
limited resale of shares purchased in a private placement subject to the satisfaction of certain
conditions, including, among other things: the availability of certain current public information
about the Company, the resale occurring not less than one year after a

- 16 -

 

party has purchased and paid for the security to be sold, the sale being through an unsolicited
“broker’s transaction” or in transactions directly with a market maker (as such term is defined
under the Securities Exchange Act of 1934, as amended) and the number of shares being sold during
any three-month period not exceeding specified limitations.

     (g) Disclosure of Information. Such Purchaser believes it has received all the information it
considers necessary or appropriate for deciding whether to purchase the securities of the Company
contemplated by this Agreement and the Transaction Documents. Such Purchaser further represents
that it or he has had an opportunity to ask questions and receive answers from the Company
regarding the securities being issued by the Company pursuant to this Agreement and the Transaction
Documents and Company’s business, properties, prospects and financial condition.

     4.3. Transfer Restrictions. The Purchaser acknowledges and agrees that its respective Note
and Warrant and, if issued, its Shares, are subject to restrictions on transfer and will bear
restrictive legends.

     4.4. Limitation on Short Selling of TVG Common Stock. The Purchaser has not and agrees not to
engage in any “short sale” (as such term is defined in Rule 3b-3 of the Securities Exchange Act of
1934, as amended) of TVG’s Common Stock or any hedging transaction, which establishes a net short
position of TVG’s Common Stock (i) from and after the First Closing Date and until the effective
date of the Merger (or, if sooner, until the termination or abandonment of the Merger Agreement or
the Merger) and (ii) if the Company effects the Merger into TVG, during the period consisting of
the sixty (60) consecutive trading days ending on the date that is one year following the effective
date of the Merger. The foregoing covenant shall lapse if the Company defaults
in the timely payment of any amount due under the Purchaser’s Note.

SECTION 5. CONDITIONS FOR CLOSING

     5.1. Conditions for the Company to Satisfy for the First Closing. The several obligations of
each Purchaser to purchase its respective Note and Warrant pursuant to the First Closing as
contemplated by this Agreement is subject to satisfaction of the following contingencies at or
prior to the First Closing:

     (a) The Company shall have obtained all third party consents required in connection herewith,
including consents from the Original Secured Parties to pledge the Collateral pari passu with the
Purchasers as security for the Notes.

     (b) The Company shall have executed and delivered to the Purchasers at Closing the Transaction
Documents.

     (c) The Company shall have satisfied all judgment liens, if any, against it filed of record
with the U.S. Patent and Trademark Office or otherwise.

- 17 -

 

     (d) The Company shall have obtained the written consent of Fusion Capital Fund II, LLC, an
Illinois limited liability company and current funding source for TVG, to the transactions
contemplated hereby in such form as the Purchasers shall require.

     (e) The Company shall have paid Whitebox Advisors a $25,000 cash origination fee
related to the transactions contemplated hereby.

     (f) Babcock & Associates, legal counsel to the Company, shall have delivered an
opinion to the Purchasers with respect to the following matters (which opinion may contain
customary exclusions and limitations that are reasonably acceptable to counsel for the
Purchasers):

	 	(i)	 	The Company is a corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware. The Company has all corporate power and authority necessary to own
its properties and to conduct its business as, to our knowledge, it is presently conducted. The
Company is qualified to do business and is in good standing in the State of California.
	 
	 	(ii)	 	The Company has the requisite corporate power and authority to execute, deliver and perform
its obligations under the Transaction Documents.
	 
	 	(iii)	 	The Transaction Documents have been duly authorized by all necessary corporate action on the
part of the Company.
	 
	 	(iv)	 	The authorized capital stock of the Company consists of 10,000,000 shares of Common Stock, par
value $0.00025 per share, and 5,000,000 shares of Preferred Stock, par value $0.00025 per share.
To our knowledge, except as described above or in the
Purchase Agreement (including the schedules and exhibits thereto), there are no other presently
outstanding preemptive rights to purchase from the Company any of the authorized but unissued stock
of the Company.
	 
	 	(v)	 	Each of the Transaction Documents, when executed and delivered by the Company, will constitute
valid and binding obligations of the Company, enforceable against the Company in accordance with
their terms.
	 
	 	(vi)	 	When issued in compliance with the provisions of the Notes and Warrants (and upon payment as
provided by the Warrants), the Shares will be validly issued, fully paid and nonassessable.
	 
	 	(vii)	 	The execution and delivery of the Transaction Documents by the Company will not result in (i)
a violation of the Company’s Amended and Restated Certificate of Incorporation or Bylaws, as
amended or (ii) a violation of any judgment or order specifically identified on the Schedules to
the Purchase Agreement, if any.

- 18 -

 

     (g) The Company shall have procured, at its expense, UCC-type insurance in form and amount
satisfactory to the Purchasers as to the perfection and priority of the Purchasers’ security
interest in the Collateral.

     5.2. Conditions for the Company to Satisfy the Option Tranche Closing. The several obligations
of each Purchaser to purchase its respective Note and Warrant pursuant to the Option Tranche
Closing as contemplated by this Agreement is subject to satisfaction of the follow contingencies at
or prior to the Option Tranche Closing:

     (a) The Company shall have obtained all third party consents required in connection herewith,
including consents from the Original Secured Parties, and the secured parties hereunder, to pledge
the collateral pari passu with the Option Tranche purchasers as security for the Option Tranche
Notes.

     (b) The Company shall make representations, warranties and covenants to the Option Tranche
purchasers as of the Option Tranche Closing in identical form as set forth in Section 3 hereof.

     (c) Legal counsel to the Company shall have delivered an opinion to the Option Tranche
purchasers as to the matters contemplated by Section 5.1(e) hereof.

     (d) The Company shall have procured, at its expense, UCC-type insurance in form and amount
satisfactory to the Option Tranche purchasers as to the perfection and priority of their security
interest in the Collateral.

SECTION 6. MISCELLANEOUS

     6.1. Governing Law. This Agreement shall be governed by the laws of the State of Minnesota as
such laws are applied to agreements between Minnesota residents
entered into and performed entirely in Minnesota.

     6.2. Survival. The representations, warranties, covenants and agreements made herein shall
survive any investigation made by the parties and the closing of the transactions contemplated
hereby. All statements as to factual matters contained in any certificate or other instrument
delivered by or on behalf of the Company pursuant hereto in connection with the transactions
contemplated hereby shall be deemed to be representations and warranties by the Company hereunder
solely as of the date of such certificate or instrument.

     6.3. Successors and Assigns. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs,
executors and administrators of the parties hereto and shall inure to the benefit of and be
enforceable by each person who shall be a holder of the Notes, the Warrants or the Shares from time
to time.

- 19 -

 

     6.4. Entire Agreement. The Transaction Documents and the other documents delivered pursuant
hereto constitute the full and entire understanding and agreement between the parties with regard
to the subjects hereof and no party shall be liable or bound to any other in any manner by any
representations, warranties, covenants and agreements except as specifically set forth herein and
therein.

     6.5. Severability. In case any provision of the Agreement shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

     6.6. Amendment and Waiver. This Agreement may be amended or modified, and any provision
hereunder may be waived, only upon the written consent of the Company and Whitebox Advisors, as
agent for the Purchasers.

     6.7. Notices. All notices, requests, consents, and other communications hereunder shall be in
writing and shall be deemed effectively given and received when delivered in person or by national
overnight courier service or by certified or registered mail, return receipt requested, or by
telecopier, addressed as follows:

	 	 	 	 	 
	 

	 	(a)
	 	if to the Company, at
	 
	 	 	 	 
	 

	 	 	 	Sutura, Inc.

17080 Newhope Street

Fountain Valley, California 92708

Attention: Anthony A. Nobles, President and Chief Executive Officer

Facsimile: (714) 427-6354
	 
	 	 	 	 
	 

	 	 	 	with a copy to:
	 
	 	 	 	 
	 

	 	 	 	Babcock & Associates

600 Anton Boulevard, 11th Floor

Costa Mesa, California 92626

Attention: Richard J. Babcock, Esq.
	 
	 	 	 	 
	 

	 	(b)
	 	if to the Purchasers, in care of:
	 
	 	 	 	 
	 

	 	 	 	Whitebox Advisors, LLC

3033 Excelsior Boulevard, Suite 300 

Minneapolis, Minnesota 55416

Attention: Jonathan Wood, Chief Financial Officer

Facsimile: (612) 253-6151
	 
	 	 	 	 
	 

	 	 	 	with a copy to:

- 20 -

 

	 	 	 	 	 
	 

	 	 	 	Messerli & Kramer P.A.

150 South Fifth Street, Suite 1800

Minneapolis, Minnesota 55402

Attention: Jeffrey C. Robbins, Esq.

Facsimile: (612) 672-3777.
	 
	 	 	 	 
	 

	 	(c)
	 	if to the Escrow Agent, at:
	 
	 	 	 	 
	 

	 	 	 	Messerli & Kramer P.A.

150 South Fifth Street, Suite 1800

Minneapolis, Minnesota 55402

Attention: Jeffrey C. Robbins, Esq.

Facsimile: (612) 672-3777.

     6.8. Indemnification by the Company. The Company agrees to indemnify and hold the Purchasers
harmless against any loss, liability, damage or expense (including reasonable legal fees and costs)
that the Purchasers may suffer, sustain or become subject to as a result of or in connection with
the breach by the Company of any representation, warranty, covenant or agreement of the Company
contained in any of the Transaction Documents.

     6.9. Expenses. At Closing, the Company shall pay the Purchaser’s counsel, Messerli
& Kramer P.A., $15,000 for its legal fees and expenses in representing the Purchasers in connection
with the transactions contemplated hereby. In addition, the Purchaser agrees to pay or reimburse
the Purchasers for their reasonable legal fees and expenses that they may incur after the date
hereof in connection with the review and approval of any matter relating to the Merger or the
granting of any waiver with respect to, the modification of any of the terms or provisions of or
the enforcement of any of the Transaction Documents.

     6.10. Titles and Subtitles. The titles of the sections and subsections of the Agreement are
for convenience of reference only and are not to be considered in construing this Agreement.

     6.11. Counterparts. This Agreement may be delivered via facsimile or other means of electronic
communication, and may be executed in counterparts, each of which shall be an original, but all of
which together shall constitute one instrument.

[signature page follows]

- 21 -

 

     IN WITNESS WHEREOF, the parties hereto have executed this Purchase Agreement as of the date
first above written.

	 	 	 	 	 	 	 	 	 	 	 
	Sutura, Inc.	 	 	 	Pandora Select Partners, L.P.,

Whitebox Hedged High Yield Partners, L.P.

and Whitebox Intermarket Partners L.P.
	By
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	Anthony A. Nobles, President and

Chief Executive Officer	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Their	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 

- 22 -

 

Exhibit A

Form of Notes

-23-

 

Exhibit B

Form of Warrants

-24-

 

Exhibit C

Form of Registration Rights Agreement

-25-

 

Exhibit D

Form of Security Agreement

-26-

 

Exhibit E

Form of Patent and Trademark Security Agreement

-27-

 

Exhibit F

Form of Escrow Agreement

-28-

 

Schedule 3.2

Stock Matters

-29-

 

Schedule 3.6

Certain Agreements and Actions

-30-

 

Schedule 3.7

Related Party Matters

-31-

 

Schedule 3.8

Changes

-32-

 

Schedule 3.9

Properties Matters

-33-

 

Schedule 3.10

Intellectual Property Matters

-34-

 

Schedule 3.11

Compliance Matters

-35-

 

Schedule 3.12

Litigation

-36-

 

Schedule 3.14

Employment Matters

-37-

 

Schedule 3.15

Registration Rights

-38-

 

Schedule 3.16

Violations

-39-

 

Schedule 3.20

Product Liability Insurance

-40-

 

Schedule 3.22

Encumbrances on Collateral

-41-

 

Schedule 3.24

Brokers or Finders

-42-exv10w3

 

Exhibit 10.3

SECURED CONVERTIBLE PROMISSORY NOTE 

      

			
	$2,000,000
	 	September 17, 2004

     FOR VALUE RECEIVED, the undersigned, Sutura, Inc., a Delaware corporation (the “Maker”),
hereby promises to pay to the order of Whitebox Hedged High Yield Partners L.P., a British Virgin
Islands limited partnership, or its assigns (the “Payee”), at such place as the Payee may designate
in writing, the principal sum of Two Million Dollars ($2,000,000), under the terms set forth
herein. This Note is one of a series of six Notes being issued by Maker on the date hereof.

1. Interest. The unpaid principal balance hereof from time to time outstanding shall bear interest
from the date hereof at the rate of twelve percent (12%) per annum.

2. Payment. Subject to earlier mandatory prepayment under Section 5 below or any default hereunder,
the principal and interest hereof is payable as follows:

     (a) Payments of $60,000 in cash of interest only are payable in arrears on December 17, 2004
and on each of March 17, June 17, September 17 and December 17, 2005; and

     (b) On March 17, 2006, the entire outstanding principal balance of this Note will be due in a
single lump sum together with all then accrued, but unpaid interest (including any then accrued,
but unpaid Contingent Additional Interest, as defined below).

     (c) In the event that, after the date hereof, Maker consummates its proposed merger (the
“Merger”) into Millenium Holding Group, Inc., a Nevada corporation (“Millenium”), pursuant to an
Agreement and Plan of Merger dated July 9, 2004 (the “Merger Agreement”) and thereafter fails:

          (i) by the earlier of:

               (A) 15 days after the date that certain registration statement to be filed
after the Merger by Millenium under the Securities Act of 1933, as amended (the “Securities Act”),
covering the issuance of its securities to Fusion Capital Fund II, LLC is declared effective by the
U.S. Securities and Exchange Commission, or

               (B) 120 days after the effective date of the Merger

to file a registration statement (the “Payee Registration Statement”) under the Securities Act
pursuant to Section 2.1 of a Registration Rights Agreement of this date among Maker, Payee and
others (the “Registration Rights Agreement”), and/or

          (ii) within seven (7) months after the effective date of the Merger to obtain effectiveness
under the Securities Act and applicable state securities laws of the Payee Registration Statement,
then for each full month (prorated for partial months) that either or both of these failures
continue (as aggregated together, the “Failure Term”), Maker shall pay in

 

 

arrears in cash, with each next otherwise scheduled payment under Sections 2(a) or (b) above (or if
the last scheduled payment under Section 2(b) has been made, then on the same day of each
succeeding month), additional interest (the “Contingent Additional Interest”) at a rate equal to
0.5% per month for the first aggregated two months of the Failure Term, and 1% per month for any
portion of the Failure Term thereafter, of the original principal balance of this Note.

     (d) Except as provided by Section 5 below, the Maker will have no right of early prepayment of
this Note.

3. Conversion.

     (a) At any time while any portion of the principal or interest of this Note is
outstanding, the Payee may give the Maker written notice (the “Payee Notice”) of its intention to
convert all or any portion of the outstanding principal and/or accrued but unpaid interest on this
Note into shares of the Maker’s Common Stock based on a conversion rate as described below (the
“Conversion Rate”). Upon receipt of the Payee’s notice, the Maker shall immediately cause
certificates dated the Payee Notice date and representing these shares to be delivered to Payee
within 20 days of, and payment shall be deemed to have been made on, the date of the Payee Notice.

     (b) Prior to the earliest of (i) March 1, 2005, (ii) the effective date of the proposed Merger
of the Maker into Millenium pursuant to the Merger Agreement (at
which time this Note and the rights and obligations of Maker hereunder shall be assigned to
and assumed by Millenium and thereafter the term “Maker” shall mean and refer to Millenium) or
(iii) the date that Maker or its controlling stockholders enter into any definitive agreement
(other than the Merger Agreement) relating to the sale, license or other disposition of all or
substantially all of the Maker’s assets, the sale or exchange of a majority of the voting stock of
Maker or the merger or consolidation of Maker into or with any other entity (a “Sale Transaction,”
with the date of the definitive agreement for the Sale Transaction being the “Sale Agreement
Date”), the Conversion Rate shall be computed as follows:

CR = $250,000,000 / N, where

“CR” is the Conversion Rate and

“N” is the number of shares of Common Stock of Maker outstanding on the date of the Payee
Notice, assuming the exercise or conversion of all then outstanding options, warrants or
other rights to acquire shares of Maker’s Common Stock or securities convertible or
exchangeable for Common Stock (or convertible or exchangeable for securities themselves
convertible or exchangeable for Common Stock), but without assuming (i) the conversion of
this Note or any other Notes that are part of this Series (together, the “Series Notes”)
or (ii) the exercise of warrants to purchase Common Stock of Maker being issued
contemporaneously herewith to the Payee and to the other holders of Notes in this Series
(together, the “Series Warrants”).

-2-

 

     (c) If on or before February 28, 2005, Maker has not consummated the Merger or entered into a
definitive agreement for a Sale Transaction, the Conversion Rate commencing on March 1, 2005 shall
thereafter be computed as follows:

CR = $100,000,000 / N.

For the purposes of this subsection 3(c), “N” is the number of shares of Common Stock of
Maker outstanding as of February 28, 2005, assuming the exercise or conversion of all
then outstanding options, warrants or other rights to acquire shares of Maker’s Common
Stock or securities convertible or exchangeable for Common Stock (or convertible or
exchangeable for securities themselves convertible or exchangeable for Common Stock), but
without assuming (i) the conversion of the Series Notes or (ii) the exercise of the
Series Warrants.

     (d) If on or before February 28, 2005, Maker consummates the Merger, then the Conversion Rate
from and after the effective date of the Merger shall be computed as follows:

CR = the lesser of:

          (i) $250,000,000 / “New N” (as defined below) or

          (ii) the average closing bid price (rounded to the nearest $0.01 per share) for
Millenium Common Stock (“Maker’s New Common Stock”) on a national stock exchange, on the Nasdaq
system or on the OTC Bulletin Board (as applicable) for the 20 trading days preceding the effective
date of the Merger (the “Testing Period”), all as reported by bigcharts.com (or if this service is
discontinued, such other reporting service acceptable to Payee). If during the Testing Period,
Millenium effects a stock split or dividend, reverse split or combination or other recapitalization
or reorganization of or relating to its outstanding Common Stock (a “Millenium Reorganization
Transaction”), then in computing the average closing bid price for Millenium Common Stock, a
proportional adjustment shall be made to the reported closing bid prices for those trading days
during the Testing Period prior to the effective date of the Millenium Reorganization Transaction.

“New N” is the number of shares of Maker’s New Common Stock outstanding immediately after
consummation of the Merger, assuming the exercise of all then outstanding options,
warrants or other rights to acquire shares of Maker’s New Common Stock or securities
convertible or exchangeable for Maker’s New Common Stock (or convertible or exchangeable
for securities themselves convertible or exchangeable for Maker’s New Common Stock), but
without assuming (i) the conversion of the Series Notes or (ii) the exercise of the
Series Warrants.

     (e) If Maker or its controlling stockholders enter into a definitive agreement relating to a
Sale Transaction (whether prior to or after consummating the Merger), then from and after the Sale
Agreement Date, the Conversion Rate shall be the lesser of the rate computed pursuant to the above
provisions or the per-share price as computed pursuant to the terms of the definitive agreement;
provided, however, that if the Sale Transaction is ultimately not consummated

-3-

 

(whether upon termination or abandonment of the definitive agreement or otherwise), then from and
after the date that Maker gives Payee notice thereof, the provisions of this subsection (e) shall
become inapplicable (unless and until Maker or its controlling stockholders enter into a different
definitive agreement relating to a Sale Transaction, whereupon, each time, this subsection shall
again become applicable).

     (f) The Conversion Rate (and, as applicable, the factors above used to compute it) shall be
adjusted proportionally for any subsequent stock dividend or split, stock combination or other
similar recapitalization, reclassification or reorganization of or affecting Maker’s Common Stock
or Maker’s New Common Stock (including any such event occurring on or after the date hereof and
prior to consummation of the Merger. In case of any consolidation or merger to which the Maker is a
party (including the Merger) other than a merger or consolidation in which the Maker is the
continuing corporation, or in case of any sale or conveyance to another corporation of the property
of
the Maker as an entirety or substantially as an entirety, or in the case of any statutory
exchange of securities with another corporation (including any exchange effected in connection with
a merger of a third corporation into the Maker), then instead of receiving shares of Maker’s Common
Stock, Payee shall have the right thereafter to receive the kind and amount of shares of stock and
other securities and property which the Payee would have owned or have been entitled to receive
immediately after such consolidation, merger, statutory exchange, sale or conveyance had the same
portion of this Note been paid or converted immediately prior to the effective date of such
consolidation, merger, statutory exchange, sale or conveyance and, in any such case, if necessary,
appropriate adjustment shall be made in the application of the provisions set forth in this Section
with respect to the rights and interests thereafter of the Payee, to the end that the provisions
set forth in this Section shall thereafter correspondingly be made applicable, as nearly as may
reasonably be, in relation to any shares of stock and other securities and property thereafter
deliverable in connection with this Note. The provisions of this subsection shall similarly apply
to successive consolidations, mergers, statutory exchanges, sales or conveyances.

4. Security. The full and timely payment of this Note, together with the Maker’s obligations under
a Purchase Agreement of this date among Maker, Payee and others (the “Purchase Agreement”) shall be
secured by a Security Agreement (including the Patent and Trademark Security Agreement attached
thereto) of this date (the “Security Agreement”) covering all of Maker’s assets. The security
interest granted under the Security Agreement shall be a first priority security interest (shared
with the other holders of the Notes that comprise this Series) subordinate to no other secured
rights.

5. Mandatory Prepayments. If Maker or its controlling stockholders enter into a definitive
agreement relating to a Sale Transaction, the Maker shall give Payee at least fifteen days prior
written notice of the proposed date for consummation of the Sale Transaction. The Maker’s notice
shall include a description of the proposed price, terms and conditions of the Sale Transaction.
Despite any other provisions hereof, the entire principal balance of this Note, and all accrued but
unpaid interest (including any Contingent Additional Interest), shall be due and payable
immediately prior to (and as a condition of) the closing on the Sale Transaction. However, within
fifteen days after receipt of Maker’s notice, Payee may give written notice to Maker that Payee
elects to convert all or any portion of the outstanding principal and/or accrued but unpaid
interest on this Note into shares of the Maker’s Common Stock (in which case, the

-4-

 

Payee’s notice will constitute a Payee Notice under Section 3 above and the portion of this Note
not so converted will be retired in cash as otherwise provided in this Section).

     The Maker shall not consummate any Sale Transaction, the price, terms and conditions of which
materially deviate from those described in Maker’s notice to the Payee, without first giving the
Payee a new notice specifying such changes. Such new notice will commence a new 15-day period
during which time Payee may give its notice to Maker as provided above.
Nothing in this Section will restrict the Maker’s ability to effect a Sale Transaction if Maker
complies with the foregoing provisions hereof.

6. Default. The occurrence of any one or more of the following events shall constitute an event of
default, upon which Payee may declare the entire principal amount of this Note, together with all
accrued but unpaid interest (including any Contingent Additional Interest), to be immediately due
and payable:

     (a) The Maker shall fail to make any required payment of principal or interest (including
Contingent Additional Interest) when due, and such failure shall continue through five days after
Payee gives written notice of such failure to Maker.

     (b) The Maker shall be in material default of any term or provision of the Purchase Agreement,
the Security Agreement, the Registration Rights Agreement or the Warrant being issued on the date
hereof by Maker to Payee (the “Warrant”), and such failure shall continue through five days after
Payee gives written notice of such default to Maker. Despite the foregoing, a failure by Maker to
timely file the Payee Registration Statement and obtain its effectiveness under the Securities Act
will not, without Maker’s subsequent failure to timely pay Contingent Additional Interest,
constitute an event of default under this subsection (b).

     (c) The Maker fails to give Payee the notice(s) required by, or consummates a Sale Transaction
in violation of, Section 5 above.

     (d) The Maker shall become insolvent or any bankruptcy, reorganization, debt arrangement or
other proceeding under any bankruptcy or insolvency law shall be instituted by or against the
Maker.

     (e) Any representation or warranty of the Maker contained in the Purchase Agreement, the
Security Agreement, the Registration Rights Agreement or the Warrant shall be untrue in any
material respect, or Maker shall fail to materially comply with any covenants or agreements of
Maker contained in any of the foregoing.

     Without limiting the above, the Maker acknowledges that payments on the various scheduled due
dates in Sections 2, and prepayment as required by Section 5, are of essence and that any failure
to timely pay any installment of principal or interest (within any permitted grace period above),
including Contingent Additional Interest, permits Payee to declare this Note immediately due in
cash in its entirety without any prior notice of any kind to Maker, except for the specific notices
provided above.

7. Applicable Law. THE VALIDITY, CONSTRUCTION AND ENFORCEABILITY OF
THE NOTE SHALL BE GOVERNED BY THE INTERNAL LAWS OF THE STATE OF

-5-

 

MINNESOTA, WITHOUT GIVING EFFECT TO CONFLICT OF LAWS PRINCIPLES THEREOF.

8. Waivers. The Maker hereby waives presentment for payment, notice of dishonor, protest and notice
of payment and all other notices of any kind in connection with the enforcement of this Note.

9. No Setoffs. The Maker shall pay principal and interest under the Note without any deduction for
any setoff or counterclaim.

10. Costs of Collection. If this Note is not paid when due, the Maker shall pay Payee’s reasonable
costs of collection, including reasonable attorney’s fees.

	 	 	 	 	 	 	 
	 	 	SUTURA, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Anthony A. Nobles, President and	 	 
	 

	 	 	 	Chief Executive Officer	 	 

-6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]